{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:22:52Z","timestamp":1768353772126,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejca.2020.04.037","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T07:01:22Z","timestamp":1600412482000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-0259","authenticated-orcid":false,"given":"Derrick L.","family":"Tao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kartika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.04.037_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41571-019-0264-7","article-title":"Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine","volume":"16","author":"Kimmelman","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-019-0262-9","article-title":"Phase I trials as valid therapeutic options for patients with cancer","volume":"16","author":"Adashek","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib3","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1056\/NEJMc1803837","article-title":"Encouraging trends in modern phase 1 oncology trials","volume":"378","author":"Chakiba","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.037_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000034","article-title":"Inadequate dissemination of phase I trials: a retrospective cohort study","volume":"6","author":"Decullier","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2020.04.037_bib5","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/annonc\/mdx076","article-title":"Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic","volume":"28","author":"Kang","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejca.2018.06.035","article-title":"A pooled analysis of published, basket trials in cancer medicine","volume":"101","author":"Hazim","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.04.037_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000330206","article-title":"Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials","volume":"81","author":"Blanco Codesido","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2020.04.037_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002505","article-title":"Risk and surrogate benefit for pediatric Phase I trials in oncology: a systematic review with meta-analysis","volume":"15","author":"Waligora","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2020.04.037_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2018.07.003","article-title":"Why is research in early-stage cancer research so low?","volume":"17","author":"Prasad","year":"2018","journal-title":"Journal of Cancer Policy"},{"key":"10.1016\/j.ejca.2020.04.037_bib10","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.ejca.2020.04.037_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJM198201283060403","article-title":"A clinical trial of amygdalin (laetrile) in the treatment of human cancer","volume":"306","author":"Moertel","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.037_bib12","first-page":"1105","article-title":"Therapeutic response in phase I trials of antineoplastic agents","volume":"70","author":"Estey","year":"1986","journal-title":"Canc Treat Rep"},{"key":"10.1016\/j.ejca.2020.04.037_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/oxfordjournals.annonc.a057716","article-title":"Responses and toxic deaths in phase I clinical trials","volume":"1","author":"Decoster","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00194562","article-title":"Response rates, duration of response, and dose response effects in phase I studies of antineoplastics","volume":"9","author":"Von Hoff","year":"1991","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.ejca.2020.04.037_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00685653","article-title":"Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan","volume":"34","author":"Itoh","year":"1994","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2020.04.037_bib16","first-page":"737","article-title":"Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience","volume":"15","author":"Yamamoto","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1008368319526","article-title":"Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials","volume":"11","author":"Bachelot","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/annonc\/mdf202","article-title":"Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs","volume":"13","author":"Sekine","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","article-title":"Risks and benefits of phase 1 oncology trials, 1991 through 2002","volume":"352","author":"Horstmann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.037_bib20","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1001\/jama.292.17.2130","article-title":"Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials","volume":"292","author":"Roberts","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ejca.2020.04.037_bib21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/cncr.22878","article-title":"Risks and benefits associated with novel phase 1 oncology trial designs","volume":"110","author":"Koyfman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.04.037_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1634\/theoncologist.2008-0046","article-title":"Characteristics and outcome of pediatric patients enrolled in phase I oncology trials","volume":"13","author":"Kim","year":"2008","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdm548","article-title":"Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy","volume":"19","author":"Italiano","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib24","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/jnci\/djs439","article-title":"Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials","volume":"104","author":"Gupta","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.04.037_bib25","first-page":"357","article-title":"Clinical benefit for patients with non-small cell\u00a0lung cancer enrolled in phase I trials","volume":"36","author":"Levy","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2020.04.037_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2013.07.089","article-title":"Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010","volume":"131","author":"Hou","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib27","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1158\/1078-0432.CCR-14-0719","article-title":"Dose-response relationship in phase i clinical trials: a European drug development network (EDDN) collaboration study","volume":"20","author":"Moreno Garcia","year":"2014","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.04.037_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.lungcan.2014.05.006","article-title":"Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution","volume":"85","author":"Raphael","year":"2014","journal-title":"Lung Canc"},{"key":"10.1016\/j.ejca.2020.04.037_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/107327481502200217","article-title":"Effect of age on clinical outcomes in phase 1 trial participants","volume":"22","author":"Mahipal","year":"2015","journal-title":"Cancer Control"},{"key":"10.1016\/j.ejca.2020.04.037_bib30","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1200\/JCO.2015.61.1525","article-title":"Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors","volume":"33","author":"Gounder","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib31","doi-asserted-by":"crossref","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2020.04.037_bib32","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/MPH.0000000000000237","article-title":"Patients in pediatric phase I and early phase II clinical oncology trials at Gustave Roussy: a 13-year center experience","volume":"37","author":"Bautista","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib33","doi-asserted-by":"crossref","first-page":"28453","DOI":"10.18632\/oncotarget.4601","article-title":"Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials","volume":"6","author":"Subbiah","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2020.04.037_bib34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ijc.30417","article-title":"Outcomes of patients >\/=65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER","volume":"140","author":"Subbiah","year":"2017","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2020.04.037_bib35","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.ejca.2020.04.037_bib36","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/pbc.26039","article-title":"Response assessment in paediatric phase I trials according to RECIST guidelines: survival outcomes, patterns of progression and relevance of changes in tumour measurements","volume":"63","author":"Carceller","year":"2016","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.ejca.2020.04.037_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/bjc.2015.477","article-title":"Phase I trial outcomes in older patients with advanced solid tumours","volume":"114","author":"Khan","year":"2016","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2020.04.037_bib38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2017.05.016","article-title":"RECIST response and variation of circulating tumour cells in phase 1 trials: a prospective multicentric study","volume":"83","author":"Massard","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.04.037_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26258","article-title":"A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials","volume":"64","author":"Dorris","year":"2017","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.ejca.2020.04.037_bib40","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MPH.0000000000000583","article-title":"Phase I and phase II objective response rates are correlated in pediatric cancer trials: an argument for better clinical trial efficiency","volume":"38","author":"Yeh","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/COC.0000000000000242","article-title":"Clinical outcomes of patients with gastrointestinal malignancies participating in phase I clinical trials","volume":"41","author":"Denson","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2018.06.003","article-title":"Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials","volume":"101","author":"Sundar","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.04.037_bib43","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1634\/theoncologist.2019-0615","article-title":"A systematic review of pediatric phase I trials in oncology: toxicity and outcomes in the era of targeted therapies","volume":"25","author":"Cohen","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2020.04.037_bib44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00043426-199809000-00005","article-title":"Phase I therapy trials in children with cancer","volume":"20","author":"Shah","year":"1998","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:42Z","timestamp":1760732862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":44,"alternative-id":["S0959804920302410"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.037","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}